Quick Answer
Semnur Pharmaceuticals, Inc. reported Operating Income of -$160.42 million for fiscal year 2025.
Semnur Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$160.42M | -3320.4% |
| 2024 | -$4.69M | -47.8% |
| 2023 | -$3.17M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$152.59M | -11656.1% | -40607.3% |
| June 30, 2025 | -$374.9K | -122.9% | -52.0% |
| March 31, 2025 | -$246.6K | +33.0% | +81.0% |
| September 30, 2024 | -$1.30M | -156.6% | -671.8% |
| June 30, 2024 | -$168.2K | +70.2% | +54.3% |
| March 31, 2024 | -$368.3K | — | +27.2% |
| September 30, 2023 | -$505.9K | — | +10.3% |
| June 30, 2023 | -$563.7K | — | — |
- Semnur Pharmaceuticals, Inc. showed a decrease of -3320.4% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Semnur Pharmaceuticals, Inc.’s operating income has declined by 4954.3% (from -$3.17 million to -$160.42 million).
- The most recent figure is from Semnur Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: